Insider Transactions

Fairmount Funds Management, a major holder ofViridian Therapeutics (VRDN), recently bought 476,190 shares. The buy increased the fund’s holdings by 35 percent, and came to a total cost of $9,999,990. This marks the first insider buy since April 2023, when the company CEO bought 4,000 shares for just over $101,000, and also made a $160,000 buy in March 2023. The company’s General Council was a small seller of shares in the past year. Overall, Viridian insiders own 1.3 percent of shares. The rare ...
Read More About This

Robert Stallings, a director atTexas Capital Bancshares (TCBI), recently bought 12,000 shares. The buy increased his holdings by 3 percent, and came to a total cost of $227,260. The director has been a regular buyer over the past few months, including over 11,000 shares in December and 13,000 shares in November and October. The company’s Chief Administrative officer has also been a buyer in the past year, picking up 1,110 shares for just over $49,000. Overall, TCBI insiders own 1.2 percent of ...
Read More About This

Joseph Reece, a director atCompass Minerals (CMP), recently added 5,000 shares. The buy increased his position by 13 percent, and came to a total cost of $106,200. This is the first insider buy since September, when the company’s Chief Commercial Officer bought 3,503 shares, paying just over $94,000. Going back to 2022, company insiders were more active as buyers, including buys from the company President and CEO. Overall, Compass insiders own 0.9 percent of shares. The salt and mineral producer has seen shares ...
Read More About This

Control Empresarial De Capitales, a major holder ofTalos Energy (TALO), recently increased their position by 130 percent. They bought 19,658,119 shares, at a cost of just under $230 million. The fund was the most recent insider buyer with two purchases in November totaling about $23 million. Otherwise, other major holders of Talos Energy have been sellers going back to mid-2023 and earlier. Overall, institutions own about 70 percent of outstanding Talos shares. Company insiders own about 22.4 percent of shares, leaving a ...
Read More About This

William Shepard, a director atCME Group (CME), recently bought 1,390 shares. The buy increased his position by 1 percent, and came to a total cost of $281,368. The director was also a buyer in late December, acquiring 278 shares at a cost just under $59,000. Over the past year, the director has made a number of other insider buys, even as other company directors and officers have been regular and consistent sellers of CME shares. Overall, CME Group insiders own 0.4 percent ...
Read More About This

James Ayers, a major holder ofFB Financial Corporation (FBK), recently added 2,000 shares. The buy increased his holdings by less than 1 percent, and came to a total cost of $70,580. Ayers was the last insider buyer with a 6,500 share pickup last August, totaling just under $199,000. Ayers made a dozen buys last year. Two company directors have also bought shares in the past year, with one of them spending just over $401,000 in total. Overall, FB Financial insiders own 25.2 ...
Read More About This

Berkshire Hathaway (BRK-A), a major holder ofLiberty SiriusXM Group (LSXMA) recently added over 2.7 million shares in two transactions. The buy increased the company’s position by 10 percent, and came to a total cost near $85 million. That’s the first insider buy since August, when the company’s Chairman bought 140,000 shares for just under $5 million. Otherwise, there have been a few insider sales, including multiple company directors and the CEO. Overall, Liberty insiders own over 10.2 percent of shares, and Berkshire ...
Read More About This

Thomas McHugh, CFO atAvadel Pharmaceuticals (AVDL), recently bought 2,000 shares. The buy increased his position by 3 percent, and came to a total cost of $29,000. The CFO was the last insider buyer with a 2,000 share pickup last August. Other company insiders, including multiple directors and the CFO have been buyers. One director with a large stake has been a seller in the past year. Overall, Avadel insiders own 4.3 percent of shares. The biopharmaceutical company has jumped 120 percent higher in ...
Read More About This